Abstract
Toll-like receptors (TLRs) are evolutionary conserved transmembrane proteins that recognize a unique pattern of molecules derived from pathogens or damaged cells, triggering robust but defined innate immune responses. TLRmediated innate and/or adaptive immune responses play an important role in a variety of diseases including infectious diseases, sepsis, autoimmune diseases, allergy, and atherosclerosis. Each TLR displays a differential expression pattern, intracellular localization and signaling pathway, resulting in distinct immune responses. A variety of new TLR ligands including agonists (e.g. urinary Tamm-Horsfall glycoprotein as a TLR4 ligand, siRNA as TLR3 or 7 ligand, Plasmodium falciparum Hemozoin as a TLR9 ligand, Profilin-like protein in Toxoplasma gondii as a TLR11 ligand) and antagonists (G-rich oligodeoxynucleotides as antagonist for TLR9) have been identified, and some of other TLR ligands are already under clinical trials. The manipulation or intervention of TLR-mediated immune responses is a possible multiple ‘Toll’ gate for future developments of immunotherapies.
Keywords: Interleukin-1 receptor-associated kinase, Oligodeoxyribonucleic acids, TNF receptor-associated factor 6, immunological disorders, TLR antagonists
Current Pharmaceutical Design
Title: ‘Toll’ Gates for Future Immunotherapy
Volume: 12 Issue: 32
Author(s): Ken J. Ishii, Satoshi Uematsu and Shizuo Akira
Affiliation:
Keywords: Interleukin-1 receptor-associated kinase, Oligodeoxyribonucleic acids, TNF receptor-associated factor 6, immunological disorders, TLR antagonists
Abstract: Toll-like receptors (TLRs) are evolutionary conserved transmembrane proteins that recognize a unique pattern of molecules derived from pathogens or damaged cells, triggering robust but defined innate immune responses. TLRmediated innate and/or adaptive immune responses play an important role in a variety of diseases including infectious diseases, sepsis, autoimmune diseases, allergy, and atherosclerosis. Each TLR displays a differential expression pattern, intracellular localization and signaling pathway, resulting in distinct immune responses. A variety of new TLR ligands including agonists (e.g. urinary Tamm-Horsfall glycoprotein as a TLR4 ligand, siRNA as TLR3 or 7 ligand, Plasmodium falciparum Hemozoin as a TLR9 ligand, Profilin-like protein in Toxoplasma gondii as a TLR11 ligand) and antagonists (G-rich oligodeoxynucleotides as antagonist for TLR9) have been identified, and some of other TLR ligands are already under clinical trials. The manipulation or intervention of TLR-mediated immune responses is a possible multiple ‘Toll’ gate for future developments of immunotherapies.
Export Options
About this article
Cite this article as:
Ishii J. Ken, Uematsu Satoshi and Akira Shizuo, ‘Toll’ Gates for Future Immunotherapy, Current Pharmaceutical Design 2006; 12 (32) . https://dx.doi.org/10.2174/138161206778743484
DOI https://dx.doi.org/10.2174/138161206778743484 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chronic Inflammation and Oxidative Stress as a Major Cause of Age- Related Diseases and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors
Current Topics in Medicinal Chemistry Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Candidate Genes Implicated in Type 1 Diabetes Susceptibility
Current Diabetes Reviews B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design The Role of Transforming Growth Factor-β1 Gene Polymorphism and Its Serum Levels in Hashimoto’s Thyroiditis
Current Pharmaceutical Biotechnology New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Epigenetics in Ocular Diseases
Current Genomics Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Metabolic Changes in Autoimmune Diseases
Current Drug Discovery Technologies Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Introduction from Editor-in-Chief
Current Rheumatology Reviews